Corrigendum: Novel chemical scaffolds to inhibit the neutral amino acid transporter B0AT1 (SLC6A19), a potential target to treat metabolic diseases.

Aditya Yadav ¹ Nishank Shah ¹ Praveen Tiwari ² Kiran Javed ¹ Qi Cheng ¹ Indrapal Singh Aidhen ² Stefan Broer ^1*

• ¹ Australian National University, Canberra, Australia
• ² Indian Institute of Technology Madras, Chennai, Tamil Nadu, India

Corrigendum on: Yadav A, Shah N, Tiwari PK, Javed K, Cheng Q, Aidhen IS and Bröer S (2020) Novel Chemical Scaffolds to Inhibit the Neutral Amino Acid Transporter B 0 AT1 (SLC6A19), a Potential Target to Treat Metabolic Diseases. Front. Pharmacol 11:140. doi: 10.3389/fphar.2020.00140 In the published article, there was an error in Fig. 4 as published. The displayed structure of compound E4 in the manuscript and on the Enamine site (Catalog ID T5320580) is that of (2-(4chloro-2,6-dimethylphenoxy)-N-isopropylacetamide). Subsequent research showed that this compound is largely inactive as an inhibitor [1], while it was evaluated in the original high throughput screen as a potent inhibitor. An IC50 of 13.7 µM (FLIPR assay) was determined with the ordered compound as shown in Table 2 of the original manuscript and confirmed by radioactive flux assay (IC50 7.7 µM). To resolve the discrepancy, we performed structural analysis and showed that the compound in the HTS collection was in fact (2-(4-chloro-3,5dimethylphenoxy)-N-isopropylacetamide). The corrected Fig. 4 and its caption appear below. The docking experiment presented in Fig. 5D remains correct, although it was performed with (2-(4-chloro-2,6-dimethylphienoxy)-N-isopropylacetamide). Subsequent research has, however, shown that the active compound binds to an allosteric site on the transporter [1]. To avoid confusion, we have since renamed the active compound JX98.